搜尋結果
Don’t Lose The Thread: Neuralink’s Problems Are Good For Neurotech
Forbes· 3 日前In January, Neuralink implanted their first participant, Noland Arbaugh, with the N1 implant at Barrow Neurological Institute ...
A Deeper Look at Anti-PD-1/PD-L1 Checkpoint Inhibitors for Cancer
Forbes· 5 日前In a previous story, I described pembrolizumab, a PD-1 targeting checkpoint inhibitor, in some ...
Gilead's Trodelvy fails to meet main goal in late-stage cancer study
Reuters· 5 日前, opens new tab said on Thursday its drug Trodelvy, tested in patients with bladder cancer who ...